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(Affiliations continued on next page)SUMMARY
Here, we present a large (n = 107,207) genome-wide
association study (GWAS) of general cognitive ability
(‘‘g’’), further enhanced by combining results with a
large-scale GWAS of educational attainment. We
identified 70 independent genomic loci associated
with general cognitive ability. Results showed
significant enrichment for genes causing Mendelian
disorders with an intellectual disability phenotype.
Competitive pathway analysis implicated the biolog-
ical processes of neurogenesis and synaptic regula-
tion, as well as the gene targets of two pharmaco-
logic agents: cinnarizine, a T-type calcium channel
blocker, and LY97241, a potassium channel inhibitor.Cell Repor
This is an open access article under the CC BY-NTranscriptome-wide and epigenome-wide analysis
revealed that the implicated loci were enriched for
genes expressed across all brain regions (most
strongly in the cerebellum). Enrichment was exclu-
sive to genes expressed in neurons but not oligoden-
drocytes or astrocytes. Finally, we report genetic
correlations between cognitive ability and disparate
phenotypes including psychiatric disorders, several
autoimmune disorders, longevity, and maternal age
at first birth.
INTRODUCTION
Genome-wide association studies (GWASs) have been highly
successful at uncovering hundreds of genetic loci associatedts 21, 2597–2613, November 28, 2017 ª 2017 The Author(s). 2597
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2014) and weight/body mass index (BMI)(Locke et al., 2015).
However, identifying genetic loci underlying cognitive ability
has been much more challenging, despite heritability of 0.5 or
greater, as determined by both classical twin studies (Deary
et al., 2009) and molecular genetic studies (Davies et al.,
2011a). In part, the difficulty with cognitive GWASs may be
caused by the relative heterogeneity in the measurement of the
cognitive phenotype. Traditionally, general cognitive ability (g)
has been defined as a latent trait underlying shared variance
across multiple subdomains of cognitive performance, psycho-
metrically obtained as the first principal component of several2598 Cell Reports 21, 2597–2613, November 28, 2017distinct neuropsychological test scores (Johnson et al., 2008).
Using this approach, several cognitive GWASs with fewer than
20,000 subjects yielded no genome-wide significant (GWS) ef-
fects (Benyamin et al., 2013; Davies et al., 2011b; Lencz et al.,
2014), while a few GWS loci were identified in larger GWAS of
35,298 (Trampush et al., 2017) and 53,949 (Davies et al., 2015)
subjects, respectively. By contrast, two independent GWASs
of height with sample sizes of approximately 30,000 subjects
each yielded 20–30 GWS hits (Gudbjartsson et al., 2008; Wee-
don et al., 2008). Allelic effect sizes were 2–5 times larger
than the largest obtained in cognitive GWASs (Trampush et al.,
2017).
Very recently, a cognitive GWAS (Sniekers et al., 2017) was
able to leverage a very brief measure of fluid intelligence, highly
correlated with psychometrically defined g, obtained in over
50,000 subjects. In combination with several traditional cognitive
GWAS cohorts, total sample size was 78,308. This sample size
permitted discovery of 18 independent GWS allelic loci, as well
as numerous additional loci from gene-based analysis. This
report was critical in demonstrating that signal could be
enhanced by combining data from cohorts with brief measures
of intelligence with data from more traditional cognitive GWASs.
A further approach to enhancing power in cognitive GWASs
has focused on educational attainment as a proxy phenotype
(Rietveld et al., 2014). It is acknowledged that this phenotype is
‘‘noisy’’, as it is influenced by non-cognitive genetic (e.g., per-
sonality; Belsky et al., 2016) and environmental (e.g., socio-eco-
nomic; Johnson et al., 2010) factors; consequently, observed
allelic effect sizes have been even smaller than those obtained
for GWASs of g (Rietveld et al., 2013). However, by utilizing a sin-
gle-item measure (years of education completed), obtained inci-
dentally in large studies of other phenotypes, this approach has
allowed investigators to obtain extremely large sample sizes.
A recent study of educational attainment in nearly 300,000 indi-
viduals identified 74 independent GWS loci (Okbay et al., 2016).
Moreover, a new technique called multi-trait analysis of GWAS
(MTAG)(Turley et al., 2017) has been developed which permits
integration of GWAS data across related traits, accounting for
the possibility of overlapping samples across studies and
requiring only summary statistics. The developers of MTAG
demonstrated its accuracy and utility in a study of traits (depres-
sion, neuroticism, and subjective well-being) that demonstrate
genetic correlations in the range of .70–.75; importantly, the
genetic correlation between cognitive performance and educa-
tional attainment has been consistently reported to be in the
same range (Davies et al., 2015, 2016; Okbay et al., 2016; Tram-
push et al., 2017; Sniekers et al., 2017). MTAG is able to quantify
the degree of ‘‘boost’’ to the signal of a single-trait GWAS,
providing an estimate of observed sample size and providing
summary statistics (allelic weights) that can then be utilized in
all downstream annotation pipelines available for GWAS output.
In the present study, we first utilized GWAS meta-analysis to
combine our prior Cognitive Genomics Consortium (COGENT)
consortium GWAS (Trampush et al., 2017) of psychometrically
defined g with the recently reported GWAS (Sniekers et al.,
2017), relying primarily on the brief measure, resulting in a com-
bined cohort of n = 107,207 non-overlapping samples measured
for cognitive performance. Next, we utilized MTAG to combine
these results with the large-scale GWAS of educational attain-
ment, resulting in further enhanced power. At each step, we per-
formed both allelic and gene-based tests. We then performed
downstream analyses on the resulting MTAG summary statis-
tics, including: (1) competitive gene set analyses to identify key
biological processes and potential drug targets implicated,
(2) stratified linkage disequilibrium score regression (LDSC) to
identify differential cell type expression, (3) transcriptome-wide
association study (TWAS) methods, to identify specific effects
of altered gene expression in the brain on cognition, and
(4) LDSC to identify genetic correlations with other anthropo-
metric and biomedical phenotypes.RESULTS
Meta-Analysis: Cognitive Performance GWASs
Meta-analysis of all non-overlapping cohorts from the two
GWASs of cognitive performance (total n = 107,207) identified
28 independent genomic loci reaching genome-wide signifi-
cance (GWS, p < 5E8) using default clumping parameters
from the Functional Mapping and Annotation (FUMA) pipeline
(Watanabe et al., 2017; Figure 1A), representing a 55.6% in-
crease in loci compared to the previous GWAS (Sniekers et al.,
2017) of cognitive performance. Two of these loci each con-
tained two uncorrelated variants with independent effects, re-
sulting in 30 independent lead SNPs. Evidence for spurious
inflation of statistical tests was quite limited for a large study of
a highly polygenic trait (l = 1.23; l1000 = 1.001; linkage disequi-
librium (LD) score intercept = 1.03; see also PP plot in Figure S1),
and overall SNP heritability was 0.168. Of the 28 GWS loci,
12 were not previously reported as GWS in published studies
of cognitive or educational phenotypes (Table S1). The majority
of the 5,610 markers reaching a nominal significance threshold
were intronic SNPs followed by those in the intergenic regions
(Table S2). As shown in Table S3, several of the GWS loci overlap
with loci related to schizophrenia, bipolar disorder, and other
neuropsychiatric phenotypes, as well as obesity/BMI and other
traits.
The significant loci harbored 88 known protein-coding genes
(Table S4), about half of which were in three large regions (Fig-
ure S2), including two well-characterized regions: the distal
16p11.2 region, in which deletions have been associated with
schizophrenia and other neuropsychiatric phenotypes (Guha
et al., 2013), and the 17q21 region, in which inversions have
been associated with neuropsychiatric disorders (Cooper
et al., 2011). Using MAGMA (Multi-marker Analysis of GenoMic
Annotation; de Leeuw et al., 2015) gene-based tests, 73 genes
were genome-wide significant (Table S5), of which 39 were over-
lapping with the 88 genes noted above, resulting in a total of 122
candidate genes with statistical evidence of association to
cognitive performance.
MTAG: Combining Cognitive Performance and
Educational Attainment GWASs
MTAG analysis combining the cognitive performance results ob-
tained above with the large educational attainment GWAS previ-
ously reported (Okbay et al., 2016), resulted in a 75% enrichment
of statistical power, effectively boosting the original sample size
of n = 107,207 to a GWAS equivalent of n = 187,812. Default
clumping procedures revealed that 70 independent genomic
loci reached genome-wide significance, with 82 independent
SNPs (Figure 1B). Similar to the GWAS results above, the PP
plot (Figure S3) demonstrated polygenicity without evidence
for artifactual inflation of statistical tests (l = 1.28; l1000 =
1.001; LD score intercept = 0.91), and overall SNP heritability
was 0.336. Of the 70 GWS loci, 34 were not previously reported
as GWS in published studies of cognitive or educational pheno-
types (Figure 2; Table S1). All but two of the 30 loci identified in
the meta-analysis remained genome-wide significant in the
MTAG results. Even these two loci showed the same direction
of allelic effects between cognitive meta-analytic GWASs andCell Reports 21, 2597–2613, November 28, 2017 2599
Figure 1. Manhattan Plots for GWAS Meta-Analysis and MTAG Analysis
(A) Manhattan plot depicting results of GWAS meta-analysis of cognitive performance. Dotted red line indicates threshold for genome-wide significance
(p < 5E08).
(B) Manhattan plot depicting results of MTAG of cognitive performance with educational attainment. Dotted red line indicates threshold for genome-wide sig-
nificance (p < 5E08).the educational GWASs. The majority of the 13,549 SNPs reach-
ing a nominal significance threshold in the MTAG analysis were
intergenic or intronic (Table S2; Figure S4). GWAS catalog anno-
tations are listed in Table S3. Within the GWS loci, 265 protein-
coding genes were identified (Table S4). Additionally, 256 genes
were significant in MAGMA gene-based tests (Table S6). Of
these genes, 85 were non-overlapping with the 265 genes within
SNP GWS loci, resulting in a total of 350 genes receiving GWS
support from the MTAG results.
As a formal validation that the MTAG methodology success-
fully predicts phenotype variance for cognitive performance,
MTAG was re-analyzed, excluding the COGENT cohorts (i.e.,
the IQ GWAS of Sniekers et al., 2017 was combined with the
educational GWAS of Okbay et al.2016). The ASPIS (Athens
Study of Psychosis Proneness and Incidence of Schizophrenia)2600 Cell Reports 21, 2597–2613, November 28, 2017and GCAP (NIMHGenes, Cognition and Psychosis Program) da-
tasets were held out as target cohorts used for calculation of
polygenic risk score modeling for ‘‘g.’’ Despite the relatively
small size of these hold-out cohorts, results show strongly signif-
icant polygenic prediction of ‘‘g’’ using MTAG-derived allele
weights (Figure 3A and 3C), accounting for more than 4% of
the variance in the GCAP cohort. For both cohorts, polygenic
prediction began to drop at PT thresholds above 0.05, suggest-
ing that theremay be some degree of saturation of signal beyond
the nominal 0.05 significance level at these sample sizes. Addi-
tional comparisons were made with IQ-only predictions (weights
derived from Sniekers et al., 2017) and education-only predic-
tions (weights derived from Okbay et al., 2016) for the same
hold-out cohorts (Figure 3B and 3D), and we found that
the MTAG-derived weights showed a 3.5 times and 3 times
Figure 2. Overlap of Genome-wide Significant Loci in this Study with
Other Recent Reports
Venn diagram depicting overlap and independence of genome-wide signifi-
cant SNP loci observed in three studies: the MTAG analysis of the present
report, the cognitive performance GWAS reported by Sniekers et al. (2017),
and the educational attainment GWAS of Okbay et al. (2016).improvement in R2 variance explained in the ASPIS cohort, for IQ
and education, respectively. For the GCAP cohort, there was a
5.1 times to 96 times improvement in R2 variance relative to IQ
or education alone.
Overlap with Intellectual Disability Genes
We compared the list of 350 genes emerging from MTAG with a
list of 621 genes known to cause autosomal dominant or
autosomal recessive Mendelian disorders featuring intellectual
disability (Harripaul et al., 2017; Vissers et al., 2016). As shown
in Table 1, a total of 23 genes identified by MTAG appeared
on this list, representing a 2-fold enrichment over chance
(hypergeometric probability p = 0.001). Examining autosomal
dominant and recessive Mendelian genes demonstrated a
somewhat stronger enrichment for autosomal dominant genes
(p = 0.0017) than autosomal recessive genes (p = 0.054).
Tissue Expression Enrichment and Competitive
Pathway Analysis
Downstream MAGMA expression profiles and competitive
pathway analysis were conducted as part of the FUMA pipeline.
MAGMA tissue expression profile analysis revealed that genes
emerging from the MTAG analysis were significantly enriched
for expression in nearly all central nervous system tissues
(except for substantia nigra and spinal cord) and that this enrich-
ment was exclusive to neural tissues (Figure 4A). Notably, the
strongest enrichment was observed for genes expressed in the
cerebellum, followed by the cortex, and slightly weaker (but still
strongly significant) enrichment in subcortical and limbic struc-
tures. Competitive pathway analysis (based on gene ontology
categories) for GWS MAGMA genes identified by MTAG re-
vealed significant enrichment of neuronal and synaptic cellular
components, as well as the biological processes of neurogene-
sis and regulation of synapse organization (Table 2, top).
Because three MTAG loci (at chromosome 3q21.31, 16p11.2,
and 17q21.31) were unusually large, each containingR15 genes
that may have disproportionately impacted enrichment results,
we re-ran the above tissue expression and pathway analyses
excluding these three regions. Results were substantively un-changed: all of the same neural tissues remained significantly
enriched, in the sameorder of significance as shown in Figure 4A,
and all of the same pathways remained significant (Bonferroni-
corrected p < .05) as shown in Table 2, except for the cellular
compartment ‘‘dendrite’’ (Bonferroni-corrected p = 0.089).
Competitive pathway analysis for drug pathways (Gaspar and
Breen, 2017) revealed that the gene targets of two drugs were
significantly enriched in the MTAG results (Table 2, bottom):
Cinnarizine, a T-type calcium channel blocker, and LY97241, a
potassium channel inhibitor. L-type calcium channel blockers
and anti-inflammatories also showed suggestive evidence of
enrichment. In a related analysis of drug classes, significant
enrichment was observed for voltage-gated calcium channel
subunits (p = 9.28E06, Bonferroni-corrected p = 5.38E04).
Stratified LD score regression (Finucane et al., 2017) also
demonstrated an enrichment of cell type expression for neu-
ronal tissues only. Notably, genes found in the neuronal expres-
sion list of Cahoy et al. (2008) were significantly enriched
(p = 0.0129; Bonferroni-corrected p = 0.0386), whereas nega-
tive results were obtained for genes expressed in oligodendro-
cytes (p = 0.4997) and astrocytes (p = 0.9057). Additionally,
using Roadmap annotations, epigenetic enrichment was stron-
gest in fetal brain tissue DNase sites and H3K4me1 primed en-
hancers, followed by adult cortical H3K27ac active enhancer
sites (see Table S7 for further details). No enrichment was
observed for any non-neuronal tissue. Again, results were not
substantively changed when the three large loci were removed
from these analyses.
Gene Expression Analyses
In order to derive specific biological insights from the broad as-
sociation loci implicated by MTAG, we performed a series of an-
alyses designed to identify individual gene expression changes
associated with cognition. First, we performed transcriptome
wide analysis (TWAS) using MetaXcan (Barbeira et al., 2016)
on MTAG SNP results in order to identify transcripts for which
upregulation or downregulation in specific neural compartments
was associated with cognition. Note that TWAS follows a similar
logic to imputation, in that an external reference (in this case,
publicly available GTEx eQTL data for 10 brain regions) is utilized
to link SNP-based summary statistics to tissue-based expres-
sion levels. As shown in Figure 4B (and detailed in Table S8),
most of the significant TWAS results are expressed across all
neural tissues, involving genes such as AMIGO3, RNF123, and
RBM6. Moreover, no individual tissue compartment was much
more strongly enriched for associations compared to the others.
However, a few strong transcriptomic associations were specific
to individual brain regions. For example, the strongest result in
hippocampus was with DAG1. TWAS demonstrated that greater
expression of this gene in the hippocampus was associated with
higher cognitive scores. However, this gene was not expressed
in other neural tissue types in the Genotype-Tissue Expression
(GTEx) database. Similarly, lower levels of ACTR1A were signif-
icantly associated with better cognition, but this transcript was
observed only in the frontal cortex.
Second, we applied a Bayesian fine-mapping approach
(CAVIAR-BF; Chen et al., 2015) to identify putative causal
SNPs within each associated locus, as defined in Table S9.Cell Reports 21, 2597–2613, November 28, 2017 2601
Figure 3. Leave-One-Out Analyses of Polygenic Risk Scores
(A) Polygenic risk score prediction for MTAG results against held-out ASPIS cohort.
(B) Comparison of MTAG, cognitive (IQ) GWAS (Sniekers et al., 2017), and educational attainment (EDU) GWAS (Okbay et al., 2016) as source of weights for
polygenic risk score prediction against held-out ASPIS cohort.
(C) Polygenic risk score prediction for MTAG results against held-out GCAP cohort.
(D) Comparison of MTAG, cognitive (IQ) GWAS (Sniekers et al., 2017), and educational attainment (EDU) GWAS (Okbay et al., 2016) as source of weights for
polygenic risk score prediction against held-out GCAP cohort.CAVIAR-BF revealed that there was strong evidence (BF =
3.71E+2) for at least 1 causal SNPwithin each of the 70 indepen-
dent MTAG loci. There is also evidence that there are at least 2
causal SNPs in 65 of the loci (BF = 3E+6) and at least 3 causal
SNPs in 47 of the loci (BF = 2.86E+6). In the extended region
analysis, there was evidence for at least 1 causal SNP (BF =
3.45E+2) and 2 causal SNPs (BF = 2.89E+6) for 70 and 63 loci,
respectively. Model search revealed that there were 386 putative
causal SNPswithin the 70 independent loci (Table S10). Lookups
of these SNPs in two brain expression quantitative trait loci
(eQTL) databases (BrainEAC [Ramasamy et al., 2014] and
CommonMind [Hauberg et al., 2017]) revealed several additional
SNP-eQTL relationships that can explain variance in the cogni-
tive phenotype (Tables S11 and S12). The most notable eQTL ef-2602 Cell Reports 21, 2597–2613, November 28, 2017fect was observed for rs3809912 on chromosome 18. This SNP,
which was GWS in the MTAG results (p = 7.06E09), was a
strong eQTL for CEP192 (p = 5.1E38, FDR < 0.01). This eQTL
was confirmed in the CommonMind database (FDR < .01), which
demonstrated that expression of 44 independent transcripts in
the frontal cortex were significantly associated with MTAG
SNPs at the FDR < .01 level. Combining annotation information
from the Mendelian gene analysis, MetaXcan TWAS, Braineac,
and CommonMind databases, we found supporting functional
evidence for 112 of the 350 candidate genes nominated by
MTAG (Table S13). The remaining 238 genes without functional
support had statistical evidence for association to cognition
but are considered to be ‘‘candidate genes’’ requiring further
functional or experimental support.
Table 1. List of Candidate Genes Emerging from MTAG Analysis Associated with Mendelian Disorders Featuring an Intellectual
Disability Phenotype
GENE CHR START MAGMA P Min MTAG P OMIM Mode Phenotype
AFF3 2 100152323 6.53E-12 6.8834E-15 NA AR nonsyndromal intellectual disability
AMT 3 49444211 1.74E-09 8.5543E-09 605899 AR glycine encephalopathy
ARFGEF2 20 47528427 7.28E-10 4.1558E-10 608097 AR periventricular heterotopia with
microcephaly
BCL11A 2 60668302 8.5E-12 3.2174E-13 617101 AD intellectual developmental disorder with
persistence of fetal hemoglobin
C12orf65 12 123707463 1.48E-10 1.8088E-11 613559 AR combined oxidative phosphorylation
deficiency 7
C12orf65 12 123707463 1.48E-10 1.8088E-11 615035 AR spastic paraplegia 55
CLN3 16 28467983 2.31E-08 1.9502E-08 204200 AR ceroid lipofuscinosis, neuronal 3
DPYD 1 97533299 0.005108 4.4603E-08 274270 AR dihydropyrimidine dehydrogenase
deficiency
DPYD 1 97533299 0.005108 4.4603E-08 274270 AR 5-fluorouracil toxicity
ERCC8 5 60159658 2.96E-07 5.5002E7 216400 AR cockayne syndrome, Type A
ERCC8 5 60159658 2.96E-07 5.5002E7 614621 AR UV-sensitive syndrome 2
FOXP1 3 70993844 6.32E-07 3.5007E-09 613670 AD mental retardation with language
impairment and autistic features
GMPPB 3 49744277 1.75E-14 6.6613E-16 613530 AR muscular dystrophy-dystroglycanopathy
(congenital w/ brain, eye anomalies),
type A,14
GMPPB 3 49744277 1.75E-14 6.6613E-16 615351 AR muscular dystrophy-dystroglycanopathy
(congenital with mental retardation),
type B,14
GMPPB 3 49744277 1.75E-14 6.6613E-16 615352 AR muscular dystrophy-dystroglycanopathy
(limb--girdle), type C, 14
KANSL1 17 44097282 1.62E-08 5.0278E-12 610443 AD Koolen-De Vries syndrome
KCNH1 1 210846555 1.04E-06 5.2513E-08 135500 AD Zimmermann-Laband syndrome
KMT2D 12 49402758 1.69E-07 4.3422E-08 147920 AD Kabuki syndrome, 1
LARGE 22 33548212 7.99E-07 5.4265E-07 613154 AR muscular dystrophy-dystroglycanopathy
(congenital w/ brain, eye anomalies),
type A, 6
LARGE 22 33548212 7.99E-07 5.4265E-07 608840 AR muscular dystrophy-dystroglycanopathy
(congenital with mental retardation),
type B, 6
MEF2C 5 88003975 1.74E-13 1.1304E-12 613443 AD mental retardation, stereotypic movements,
epilepsy, and/or cerebral malformations
MEF2C 5 88003975 1.74E-13 1.1304E-12 613443 AD chromosome 5q14.3 deletion syndrome
NFIX 19 13096422 2.45E-06 5.3017E-09 602535 AD Marshall-Smith syndrome
NFIX 19 13096422 2.45E-06 5.3017E-09 614753 AD Sotos syndrome
PDE4D 5 58254865 9.13E-08 3.6537E-07 614613 AD Acrodysostosis 2 with or without hormone
resistance
SHANK3 22 51102843 2.7E-10 8.0006E-08 606232 AD Phelan-McDermid syndrome
ST3GAL3 1 44161495 3.58E-13 1.6388E-10 611090 AR mental retardation, autosomal recessive 12
SUOX 12 56380964 3.07E-05 4.1129E-08 272300 AR sulfite oxidase deficiency
TCF4 18 52879562 1.02E-06 3.5713E-05 610954 AD Pitt-Hopkins syndrome
THRB 3 24148651 0.000682 4.6883E-06 188570 AD thyroid hormone resistance
THRB 3 24148651 0.000682 4.6883E-06 274300 AR thyroid hormone resistance, autosomal
recessive
UBA7 3 49832640 2.11E-13 6.6613E-16 NA AR nonsyndromal intellectual disability
AD, autosomal dominant; AR, autosomal recessive.
Cell Reports 21, 2597–2613, November 28, 2017 2603
Figure 4. Tissue Expression and Transcriptome-wide Gene Expression Results
(A) Tissue expression profile analysis for genome-wide significant genes (as defined by MAGMA) emerging from the MTAG analysis. Gene results were signif-
icantly enriched for expression in nearly all central nervous system tissues (except for substantia nigra and spinal cord) but no tissues outside the central nervous
system.
(legend continued on next page)
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Table 2. Competitive Pathway Analyses of MTAG Results
GO Category Name NGENES BETA BETA_STD SE P Pbon
GO_cc:go_neuron_part 1204 0.155 0.0385 0.0304 1.84E-07 0.002008
GO_cc:go_neuron_projection 898 0.179 0.0388 0.0352 1.84E-07 0.002009
GO_bp:go_neurogenesis 1355 0.148 0.0388 0.0291 1.92E-07 0.002092
GO_cc:go_synapse 718 0.198 0.0386 0.0393 2.25E-07 0.002455
GO_cc:go_synapse_part 580 0.21 0.0369 0.0436 7.37E-07 0.008026
GO_cc:go_dendrite 430 0.229 0.0348 0.0501 2.49E-06 0.027087
GO_bp:go_regulation_of_synapse_organization 106 0.447 0.034 0.0987 2.94E-06 0.031982
GO_bp:go_regulation_of_synapse_structure_or_activity 223 0.291 0.032 0.0671 7.36E-06 0.080154
GO_bp:go_regulation_of_nervous_system_development 723 0.166 0.0325 0.0385 7.84E-06 0.085334
GO_bp:go_modulation_of_synaptic_transmission 291 0.253 0.0317 0.059 9.41E-06 0.102429
GO_bp:go_calcium_dependent_cell_cell_adhesion_
via_plasma_membrane_cell_adhesion_molecules
26 1.06 0.0402 0.259 2.06E-05 0.224726
GO_cc:go_postsynapse 356 0.224 0.031 0.0553 2.64E-05 0.287583
GO_cc:go_neuron_spine 116 0.379 0.0302 0.0939 2.75E-05 0.299998
GO_cc:go_cell_projection 1710 0.103 0.0301 0.0258 3.36E-05 0.365381
GO_bp:go_regulation_of_cell_development 808 0.144 0.0297 0.0365 3.99E-05 0.434751
Drug Name NGENES BETA BETA_STD SE P Pbon
CINNARIZINE 9 1.62 0.036 0.355 2.61E-06 0.007071
LY97241 2 3.65 0.0382 0.842 7.59E-06 0.020535
CELECOXIB 45 0.632 0.0314 0.159 3.49E-05 0.094545
ISRADIPINE 8 1.59 0.0334 0.404 4.18E-05 0.11317
NITRENDIPINE 12 1.19 0.0305 0.323 1.19E-04 0.323151
ABT-639;ML218;TTA-A2;Z944 3 2.31 0.0297 0.641 1.59E-04 0.429388
NEUREGULIN-1;NEUREGULIN-2 2 2.39 0.0251 0.669 1.75E-04 0.473469
FLUNARIZINE 6 1.58 0.0287 0.457 2.67E-04 0.723503
GLUCOCORTICOIDS 2 3.68 0.0386 1.08 3.22E-04 0.872117Genetic Correlations with Other Phenotypes
LD score regression was carried out across 89 traits in 15 broad
phenotypic categories in LD Hub (Zheng et al., 2017): (1) aging,
(2) anthropometric, (3) autoimmune, (4) brain volume, (5) cardio-
metabolic, (6) education, (7) glycemic, (8) lipids, (9) lung function,
(10) neurological, (11) personality, (12) psychiatric, (13) reproduc-
tive behavior, (14) sleep, and (15) smoking behavior (Figure 5;
Table S14). We performed LD score regression separately for
the results of our initial meta-analysis and for the MTAG results.
For comparison, we also present LD score regression results for
the educational attainment GWAS of Okbay et al. (2016). It
should be noted that only 14 phenotypes were examined for ge-
netic correlation in that publication.
Cognition appeared to be strongly associated at the genetic
level with aging, education, personality, neuropsychiatric disor-
ders, reproductive behavior, and smoking behavior. Strong
association with parental age at death was observed for both
the GWASmeta-analysis and MTAG results. Meanwhile, moder-
ate associations with anthropometric traits were observed,(B) Circular Manhattan Plot for MetaXcan results based on MTAG of cognitive per
is as follows: ACC, Anterior Cingulate Cortex; CDBG, Caudate – Basal Gang
FCTX, Frontal Cortex; HIPP, Hippocampus; HYPO, Hypothalamus; NACMB, N
corrected p < 0.05.although associations with brain volumes were surprisingly
modest, except for total intracranial volume (rg for MTAG
results = 0.31, p = 7.37E-19). While many of these correlations
have been described previously (Hagenaars et al., 2016; Okbay
et al., 2016; Sniekers et al., 2017; Trampush et al., 2017), two re-
sults observed in the present study were not reported in those
prior publications. First, we report a strong positive genetic cor-
relation between cognitive performance andmaternal age at first
birth (rg forMTAG results = 0.63, p = 2.36E163) and inverse cor-
relation with parental number of children ever born (rg for MTAG
results = 0.22; p = 6.91E13). It is possible that these effects
are mediated by years of higher education, insofar as correla-
tions were even stronger with educational attainment (rg for
parental age at first birth = 0.72, p = 2.24E244; rg for number
of children =0.26, p = 3.34E18). As with any other regression
relationship, a role for unmeasured mediators, such as propen-
sity for delayed gratification, cannot be ruled out. Second, we
observed modest, yet nominally significant, inverse correlations
between cognition and autoimmune diseases such as eczemaformance with educational attainment. From inner circle out, GTEX tissue order
lia; CRBHM, Cerebellar Hemisphere; CRBLM, Cerebellum; CRTX, Cortex;
ucleus Accumbens; PUTM, Putamen. GWAS threshold is set at Bonferroni-
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and Crohn’s disease, attaining Bonferroni significance for rheu-
matoid arthritis (rg for MTAG results = 0.2086; p = 1.60E08).
There was also a Bonferroni-significant positive genetic correla-
tion with celiac disease (rg for MTAG results = 0.1922;
p = 0.0001). While results of cross-trait analyses were largely
consistent using either the GWAS results, the MTAG results, or
the previously published educational attainment datasets, there
were notable divergences in correlations with psychiatric pheno-
types, especially schizophrenia and bipolar disorder.
DISCUSSION
Uncovering the molecular genetic basis of individual differences
in cognitive performance can have a significant impact on our
understanding of neuropsychiatric disorders, which are both
phenotypically (Burdick et al., 2011; Ferreri et al., 2011; Keefe
and Harvey, 2012; Snyder, 2013) and genetically (Lencz et al.,
2014; Smeland et al., 2017; Stergiakouli et al., 2017) correlated
with cognition, as well as numerous non-psychiatric health-rele-
vant phenotypes (Hagenaars et al., 2016), which also demon-
strate significant genetic correlations with cognitive function.
Here, we have presented the largest GWAS of cognition to
date, with 107,207 individuals phenotypically characterized for
performance on standardized tests measuring general cognitive
ability. Results were further enhanced by utilizing a relatively new
approach to allow meta-analysis with a large-scale GWAS of
educational attainment, which is highly (though not perfectly)
correlated with cognitive ability at the genetic level. With this
approach, we were able to identify 70 genomic loci significantly
associated with cognition, implicating 350 candidate genes un-
derlying cognitive ability. In total, we found that common SNPs
were able to account for roughly half of the overall heritability
of the phenotype as determined by prior family studies (Plomin
and Deary, 2015).
Downstream analysis confirmed an important role for neuro-
developmental processes in cognitive ability, consistent with
implications from the education GWAS (Okbay et al., 2016). Sig-
nificant genes were more strongly enriched for expression in
fetal brain tissue than adult tissue. Results were also enriched
for genes implicated in early neurodevelopmental disorders,
and neurogenesis was the most strongly enriched GO biological
process. At the same time, it is important to emphasize that adult
neural tissues were also strongly represented in the results, and
multiple synaptic components were significant in the pathway
analysis. In this context, it is noteworthy that many cellular pro-
cesses necessary for early neurodevelopment are also involved
in adult synaptic plasticity. This duality is represented by several
significant genes emerging from our analysis. CELSR3 encodes
an atypical cadherin plasma membrane protein involved in long-
range axon guidance in neurodevelopment through planar cell
polarity signaling (Chai et al., 2015) but is also necessary for adult
formation of hippocampal glutamatergic synapses (Thakar et al.,Figure 5. Genetic Correlations for GWAS Meta-analysis of Cognitive
GWAS of Educational Attainment
Genetic correlations (rg) between cognitive phenotypes and other publicly availab
(labeled METAL and MTAG, respectively) refer to results of the cognitive meta-
educational attainment GWAS of Okbay et al. (2016).2017). Similarly SEMA3F is a negative regulator of dendritic
spine development in adult hippocampus (Tran et al., 2009) but
embryonically serves as an endogenous chemorepellent, guid-
ing septohippocampal fibers away from non-limbic regions of
developing cortex (Pascual et al., 2005).
While synaptic mechanisms were strongly implicated by our
results, it is noteworthy that there was no statistical evidence
for enrichment of genes expressed in oligodendrocytes or astro-
cytes. While developmental disorders primarily affecting oligo-
dendrocytes, such as metachromatic leukodystrophy, are
marked by cognitive impairment (Faust et al., 2010), it is possible
that individual variation in cognitive ability within the normal
range is less directly under genetic control via white matter
mechanisms. By contrast, strong evidence was provided for
the involvement of genes expressed in the cerebellum.
Converging evidence from functional imaging studies, lesion
studies, structural connectivity, and evolutionary considerations
strongly implicate a role for the cerebellum in higher cognitive
functions (Buckner, 2013), possibly through the mechanism of
prediction and error-based learning (Sokolov et al., 2017).
By utilizing TWAS methodology, we were able to isolate
expression effects of specific genes within some of our broad
GWAS loci. For example, ACTR1A, which lies near the GWAS
peak at chromosome 10q24, encodes a microtubular dynactin
protein involved in retrograde axon transport (Moughamian
et al., 2013). Other genes at this locus were not significant in
the TWAS analysis (although a role in cognition cannot be ruled
out, given the limited sample size in the reference brain expres-
sion datasets in GTEx). However, most of the genes implicated
by TWAS were clustered in a few ‘‘hot’’ genomic loci, which
may represent topologically associated domains (TADs) under
the control of a shared three-dimensional chromatin structure
(Gonzalez-Sandoval and Gasser, 2016). Whether effects on
cognition are driven by all differentially expressed genes within
such loci or if specific effects can be disentangled through
experimental means remains to be determined.
The overlap of 23 genes from our results with known genes for
Mendelian disorders characterized by intellectual disability has
several implications. First, this statistically significant enrichment
provides partial validation of our MTAG results. Second, genes
with known mutations of large effect, when combined with our
data demonstrating SNPs with smaller regulatory effects on
the same phenotype (cognition), can be considered an ‘‘allelic
series’’ (Plenge et al., 2013)—a natural set of experiments
powerfully demonstrating directional information (in the form of
a dose-response curve) regarding gene function. Such informa-
tion can be leveraged for the identification of novel drug
targets. Third, converging evidence across the Mendelian and
GWAS lists can aid interpretation of specific pathways and mo-
lecular processes that are necessary to normal neuronal function
and vice versa. For example, two genes on both the Mendelian
and GWAS lists (GMPPB and LARGE) are associated withPerformance, MTAG of Cognition and Educational Attainment, and
le GWAS results, based on LD score regression. The first and second columns
analyses in the present report. The third column displays correlations for the
Cell Reports 21, 2597–2613, November 28, 2017 2607
dystroglycanopathies with mental retardation. This information
provides context for the observation that DAG1, which encodes
dystroglycan 1, is the strongest TWAS result in the hippocam-
pus.DAG1 is necessary for GABAergic signaling in hippocampal
interneurons (Fr€uh et al., 2016). While dystroglycanopathies are
most prominently characterized by muscular dystrophy and
retinal abnormalities, it is possible that all of these genes play a
role in hippocampal synapse formation that is relevant to normal
cognitive ability.
As noted above, one of the most important aims of GWAS
studies is the identification of novel drug targets, and it has
been suggested that targets with supporting GWAS evidence
may be twice as successful in clinical development compared
to those without such evidence (Nelson et al., 2015). Our drug
set enrichment analysis pointed to several potential nootropic
mechanisms. Most notably, the strongest signal was for cinnar-
izine, a T-type calcium channel inhibitor typically prescribed for
seasickness. In the present study, we discovered an associa-
tion of cognition to CACNA1I, which encodes one component
of the voltage-dependent T-Type Cav3.3 channel and has
been previously associated with schizophrenia (Schizophrenia
Working Group of the Psychiatric Genomics Consortium,
2014). While cinnarizine has strong antihistamine activity and
may be inappropriate for general cognitive enhancement, a
novel agent targeting Cav3.3 has shown nootropic activity in
preclinical models (Moriguchi et al., 2012). In addition to gene
set results suggesting a potential role for calcium and potas-
sium channel regulation, single-gene results also point toward
a potential role for the metabotropic glutamate receptor en-
coded by GRM3. This gene is also implicated in schizophrenia
(Schizophrenia Working Group of the Psychiatric Genomics
Consortium, 2014), and drugs targeting GRM3 have been sug-
gested as a potential treatment (Lencz and Malhotra, 2015);
however, a large-scale trial of one such agent was unsuccessful
in treating psychotic symptoms (Downing et al., 2014). Based
on the present results, future studies may seek to examine a
role for such compounds in cognitive remediation. It is also
noteworthy that the present study identified genome-wide sig-
nificant evidence implicating three phosphodiesterase genes:
PDE1C, PDE2A, and PDE4D. In particular, there is growing in-
terest in PDE2A inhibitors as potential agents for cognitive
enhancement (Trabanco et al., 2016), and evidence suggests
that these agents may enhance synaptic plasticity via presyn-
aptic modulation of cAMP hydrolysis (Ferna´ndez-Ferna´ndez
et al., 2015). PDE4D inhibition is also under investigation as
a potential therapy for neurodegenerative disease (Ricciarelli
et al., 2017).
It is important to emphasize that uncovering genetic variation
underlying general cognitive ability in the healthy population
does not have deterministic implications. As has been previously
explicated in similar studies (Trampush et al., 2017), effect sizes
for each allele are extremely small (R2 < 0.1% for even the stron-
gest effects), and the combined effects genome-wide predict
only a small proportion of the total variance in hold-out samples
(Figure 3). Thus, results of the present study do not hold the po-
tential for individual prediction or classification. Nevertheless,
the results may still have substantial impact on our understand-
ing of molecular mechanisms underlying cognitive ability.2608 Cell Reports 21, 2597–2613, November 28, 2017EXPERIMENTAL PROCEDURES
Subject Details
The cohorts included in the current study were described in detail in two prior
reports on cognitive performance (Sniekers et al., 2017; Trampush et al., 2017)
and one prior report on educational attainment (Okbay et al., 2016). Sample
sizes for these three studies were n = 78,308, n = 35,298, and n = 328,917,
respectively. For the present study, two cohorts reported in Trampush et al.
(2017) were excluded, so that cohorts included will be independent from those
reported in Sniekers et al. (2017): (1) Minnesota Center for Twin and Family
Research (MCTFR) and (2) Lothian Birth Cohort 1936 Study. As a result, sam-
ple sizes decreased from the originally reported n = 35,298 to n = 28,899. All
phenotypes includedwere as reported originally in the respective publications.
All subjects provided written, informed consent to procedures that were
approved by local review boards for the institutions at which each cohort
was collected. Further details are available in the supplementary materials to
those three publications.
GWAS Quality Control
Markers reported in the prior COGENT study (Trampush et al., 2017) were up-
dated to build 37 coordinates but were originally imputed against the HRC
(Haplotype Reference Consortium) reference panel (McCarthy et al., 2016)
via the Sanger imputation server. To ensure that markers, allele frequencies,
and alleles were aligned to the 1000 Genomes phase 3 reference panel
(1000 Genomes Project Consortium et al., 2015), the COGENT summary sta-
tistics (Trampush et al., 2017) were checked using the EasyQC pipeline (Win-
kler et al., 2014), which allows summary statistics to be aligned and checked
against a reference panel of choice.We used the default 1000 Genomes phase
3 reference panel (1000 Genomes Project Consortium et al., 2015), provided
along with the EasyQC package. Markers were inspected for allele frequency
outliers, presence of duplicated markers, and allele mismatches with the 1000
Genomes reference panel. Quality control filters for INFO score < 0.6 and
n < 10,000 were additionally implemented. After EasyQC quality control,
8,040,131 SNPs were available for analysis. Only 87 SNPs were excluded
due to allele mismatches, 13,276 SNPs were excluded due to allele frequency
mismatches from the 1000 Genomes phase 3 reference panel, 283,163 were
found to be duplicates and excluded, 104 SNPs were found on the HRC refer-
ence panel, but not on the 1000 Genomes phase 3 reference panel, and
2,723,493 SNPs had sample sizes <10,000 individuals. None of the SNPs
failed the INFO score < 0.6 cutoff. The same set of SNPs was utilized for sub-
sequent reduced sample meta-analysis without the overlapping LBC1936 and
MCTFR cohorts in Trampush et al. (2017). As the other prior studies of cogni-
tive performance (Sniekers et al., 2017) and education (Okbay et al., 2016)
were imputed to the 1000 Genomes phase 3 reference panel, summary statis-
tics were used as provided (https://ctg.cncr.nl/software/summary_statistics;
https://www.thessgac.org/data).
GWAS Meta-Analysis
Fixed-effect meta-analysis was conducted between Sniekers et al. (2017) and
independent cohorts reported in Trampush et al. (2017) using the METAL
package (Willer et al., 2010). To ensure that results of the meta-analysis
were contributed by both studies, markers present only in Sniekers et al.
(2017) or Trampush et al. (2017), but not in both, were excluded for further anal-
ysis. The number of available markers after QC filtering was 7,357,080.
Because the GWAS of Sniekers et al. (2017) utilized the sample-size-weighted
method to perform meta-analysis across its own cohorts and did not report
variance terms, our meta-analysis was conducted using the sample-size-
weighted method.
Multi-Trait Analysis for GWAS (MTAG)
To further enrich genetic signals, we employed a newly developed methodol-
ogy that integrates LD score regression and meta-analysis techniques across
related traits: MTAG (Turley et al., 2017). MTAG (v0.9.0) was applied to the
METAL results described immediately above and combined with summary
statistics from the recent, large-scale education GWAS (Okbay et al., 2016).
MTAG analysis allows the boosting of genetic signals across related traits
and has been found to be effective in resolving unknown sample overlaps,
generating trait-specific effect estimates weighted by bivariate genetic
correlation. The MTAG QC pipeline aligned all alleles across both sets of
summary statistics and ensured that SNPs were present across all datasets.
SNPs that were not present in either dataset were removed. The final SNP
count for MTAGwas 7,333,576. TheMTAGmethodology proceeds by: (1) esti-
mating the variance-covariance matrix of the GWAS estimation error, by
using a series of LD score regressions, of which, under the known properties
of LD score regression, captures relevant sources of estimation error,
incorporating population stratification, unknown sample overlap, and cryptic
relatedness, (2) estimating the variance-covariance of SNP effects using
the maximum likelihood procedure reported in Turley et al. (2017), and
(3) computing the MTAG estimator for each SNP and each trait. Summary
statistics consisting of SNP, CHR, BP, per SNP sample size, BETA, and SE
for each trait were entered to the MTAG python command line. The resulting
effect estimates and p values are interpreted the same as single-trait GWAS,
which allows standard downstream follow-up analysis on the summary
statistics. The python code for MTAG is available at https://github.com/
omeed-maghzian/mtag.
Functional Mapping and Annotation for GWAS
GWAS summary statistics from the METAL meta-analysis and MTAG analysis
were separately entered into the FUMA pipeline (Watanabe et al., 2017). The
FUMA pipeline enables fast prioritization of genomic variants and genes and
permits interactive visualization of genomic results with respect to state-of-
the-art bioinformatics resources. Manhattan and QQ plots are produced,
and MAGMA gene-based analysis is performed, accounting for gene size
and LD structure. FUMA was also utilized to perform competitive gene-set
analyses for GO cell compartment and biological process categories using
the Molecular Signature Database (MsigDB 5.2). A separate competitive
gene-set analysis was also conducted for the drug-based pathways previously
described by Gaspar and Breen (2017). The pipeline also generates aggre-
gated statistics for independent loci, lead SNPs, tagged genes, and supple-
mentary plots—including SNP and locus annotations. Default clumping
parameters are: GWAS p value < 5E08; r2 threshold to define LD structure
of independent SNPs > 0.1; maximum p value cutoff < 0.05; population for
clumping = EUR; minor allele frequency filter > 0.01; maximum distance be-
tween LD blocks to merge into a single locus= 250 kb. Follow-up queries
were then made for independent loci of the cognitive performance meta-anal-
ysis as well as the MTAG results and compared against summary statistics for
the prior cognitive and education GWAS. For purposes of comparison, loci in
which the lead SNPs were within 500kb of each other were considered
overlapping.
We compared the list of genes resulting from the MTAG analysis (including
all genes within GWS SNP loci, as well as GWS genes identified with MAGMA)
with a list of 621 genes known to cause autosomal dominant or autosomal
recessive Mendelian disorders featuring intellectual disability. This list is pri-
marily derived from a recent comprehensive review (Vissers et al., 2016), sup-
plemented by a subsequent large-scale study of consanguineous multiplex
families (Harripaul et al., 2017). A total of 193 autosomal dominant genes
were identified, and a total of 413 autosomal recessive genes were identified.
Fifteen genes were annotated as causing both autosomal dominant and auto-
somal recessive disorders with intellectual disability. Statistical significance
was determined by probabilities derived according to the hypergeometric dis-
tribution. For this purpose, the total pool of autosomal genes was set to 19,011
(per Gencode).
Polygenic Risk Prediction for Independent Datasets
To validate that the genetic architecture elucidated via the MTAG methodol-
ogy, we attempted to predict the phenotypic variance of general cognitive
function in two of the independent COGENT cohorts (ASPIS and GCAP).
MTAG analysis was conducted as above, but removing the COGENT cohorts.
Polygenic score prediction across multiple thresholds of PT was conducted
using PRSice (Euesden et al., 2015). To compare the effectiveness of
MTAG, we also conducted polygenic risk prediction using IQ-only and educa-
tion-only summary statistics. Finally, R2 across SNP thresholds is compared to
obtain the degree of improvement in terms of the ratio of MTAG PRS R2 values
versus those of IQ or education PRS R2.Stratified LD Regression: Cell Type Expression and Epigenomics
Functional characterization of GWAS summary statistics was carried out via
stratified LD regression to investigate if heritability of cognitive performance
is enriched in specific tissue or cell types. Summary statistics were first sub-
jected to baseline partitioned heritability and thereafter passed through a
cell-type-specific functional characterization pipeline (Finucane et al., 2017).
Cell-type characterization includes the DEPICT tissue expression database,
GTEX tissue expression, IMMGEN immune cell types, CAHOY brain level
cell types, and the ROADMAP cell epigenomic marks.
Transcriptome-Wide Analysis and Brain Expression lookups
Transcriptome-wide analysis was carried out via MetaXcan (Barbeira et al.,
2016), which allows for GTEx brain expression data to be integrated with
GWAS summary statistics. MetaXcan computes downstream phenotypic as-
sociations of genetic regulation of molecular traits, using elastic, adjustment
for model uncertainty, and colocalization of GWAS and eQTL signals (Barbeira
et al., 2016). GTEx Version 6, brain tissue expression profiles and sample sizes
include the anterior cingulate cortex (n = 72); caudate-basal ganglia (n = 100);
cerebellar hemisphere (n = 89); cerebellum (n = 103); cortex (n = 96); frontal
cortex (n = 92); hippocampus (n = 81); hypothalamus (n = 81); nucleus accum-
bens (n = 93); and putamen (n = 82).
Bayesian Fine-Mapping Analysis and Functional Annotations
To identify potential causal variants in each of the independent loci, CAVIAR-
BF is implemented to a region±50KBof a leadSNP identified in theMTAGanal-
ysis. We followed similar procedures setting prior effect distribution sa to 0.1 in
the model, which was recommended for GWAS studies (Chen et al., 2015;
https://bitbucket.org/Wenan/caviarbf). The prior probability of being causal
for each SNP is set to 1/m, where m is the number of SNPs. Bayes factor
was calculated for three model sets for independent loci, which modeled for
1, 2, and up to 3 causal SNPs within each independent regions, after which a
model search algorithm searches and identifies the putative causal SNPs.
These SNPs were then annotated using the Ensembl Variant Effect Predictor
(McLaren et al., 2016). The analysis was repeated for extended regions taking
into account the length of the independent loci identified by earlier FUMA pro-
cedures modeling for either 1 or 2 causal SNPs. SNPs identified by the two
stage CAVIARBF analysis were then examined for potential gene expression
in the BrainEAC (Ramasamy et al., 2014) and CommonMind (Hauberg et al.,
2017) databases. BrainEAC top SNP lookups were for the following tissue
expression across n = 134 individuals: aveALL, all area combined; CRBL, cer-
ebellum; FCTX, frontal cortex; HIPP, hippocampus; MEDU, medulla; OCTX,
occipital cortex; PUTM, putamen; SNIG, substantia nigra; TCTX, temporal cor-
tex; THAL, thalamus; and WHMT, white matter. Finally, the prefrontal cortex
lookup was included as part of the CommonMind consortium brain expression
profile in n = 467 genetically inferred Caucasian samples.
Linkage Disequilibrium Score Regression
LD score regression allows genetic correlations to be computed across traits
(Bulik-Sullivan et al., 2015a, 2015b), which allows further insights to be drawn
from understanding the degree to which genetic architecture are shared
across traits. To further examine potential traits that overlap with the cognitive
architecture from the cognition meta-analysis results and MTAG results, LD
score regression was conducted via the LD-hub pipeline, a centralized trait
database (Zheng et al., 2017). LD score regression was carried out across
89 traits in 15 broad phenotypic categories: (1) aging, (2) anthropometric,
(3) autoimmune, (4) brain volume, (5) cardiometabolic, (6) education, (7) glyce-
mic, (8) lipids, (9) lung function, (10) neurological, (11) personality, (12) psychi-
atric, (13) reproductive behavior, (14) sleep, and (15) smoking behavior. Very
recent reported GWAS summary statistics for attention deficit hyperactivity
disorder (ADHD; Demontis et al., 2017) and intracranial volume (ICV; Adams
et al., 2016) were included as additional phenotypes. For comparison, we
also present LD score regression results for the educational attainment
GWAS of Okbay et al. (2016). It should be noted that only 14 phenotypes
were examined for genetic correlation in that publication. It should be noted
that the MHC (Major Histocompatibility Complex) region was redacted from
all datasets prior to LD score regression analysis, as per standard protocol
at LD-Hub.Cell Reports 21, 2597–2613, November 28, 2017 2609
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